

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA 445)
Policy No:	PCN 267-2017
Date of Issue	July 2017
Review Date:	<p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.</i></p> <p><i>The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p>Recommendations:</p> <p>The PCN recommends Certolizumab pegol and secukinumab as treatment options for treating active psoriatic arthritis after inadequate response to DMARDs in line with NICE and the associated treatment pathway.</p> <p>Prescribing will be by hospital specialists only, in line with NICE TA445 using Blueteq initiation and continuation forms.</p> <p>Certolizumab pegol and Secukinumab will be considered RED on the traffic light system</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> NICE TA 445- Certolizumab pegol and Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs https://www.nice.org.uk/guidance/ta445/resources/certolizumab-pegol-andsecukinumab-for-treating-active-psoriatic-arthritis-after-inadequate-response-to-dmards-pdf-82604786303941 	
Date taken to Area Prescribing Committee	5 th July 2017
Agreed by APC members	17 th July 2017